RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Motor Neuron Disease: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
An integrative transcriptomic atlas of ALS and aging skeletal muscle defines shared and distinct molecular programs of degeneration.
Grima-Terrén Mercedes et al., Proceedings of the National Academy of Sciences of the United States of America (20 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42879493/
- 2.
Factors associated with post-tracheostomy survival in Amyotrophic Lateral Sclerosis.
Maccabeo Alessandra et al., Amyotrophic lateral sclerosis & frontotemporal degeneration (19 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42895434/
- 3.
Mapping care interventions for people living with motor neurone disease: a living evidence and gap map
Danielle Pollock et al., Figshare (18 October 2026)
https://doi.org/10.6084/m9.figshare.34691328
- 4.
Mapping care interventions for people living with motor neurone disease: a living evidence and gap map.
Pollock Danielle et al., Neurodegenerative disease management (18 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42893382/
- 5.
Peripheral and cerebrospinal fluid inflammatory markers in sporadic amyotrophic lateral sclerosis an exploratory cross-sectional association study.
Wełnicka-Wesołowska Agnieszka et al., Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (17 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42891860/
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Functional Outcomes and Control Using Synchron BCI - Australia
NCT07533903 · Recruiting · Synchron, Inc.
Ages 21 and over
https://clinicaltrials.gov/study/NCT07533903
- 2.
A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.
NCT07369076 · Recruiting · Phase 1 / Phase 2 · Nura Bio
Ages 18 to 80
https://clinicaltrials.gov/study/NCT07369076
- 3.
Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis
NCT07401121 · Recruiting · Phase 1 · Celosia Therapeutics Pty Ltd
Ages 18 to 80
https://clinicaltrials.gov/study/NCT07401121
- 4.
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
NCT07023835 · Recruiting · Phase 2 · Zydus Therapeutics Inc.
Ages 18 and over
https://clinicaltrials.gov/study/NCT07023835
- 5.
Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS
NCT06126315 · Recruiting · Phase 2 / Phase 3 · Mario Negri Institute for Pharmacological Research
Ages 18 and over
https://clinicaltrials.gov/study/NCT06126315
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Motor Neuron Disease
Motor neuron disease (MND), also known as ALS, is a progressive neurodegenerative condition that destroys the nerve cells controlling movement, leading to muscle weakness, paralysis, and eventually respiratory failure. Most cases are fatal within 2-5 years of diagnosis. Riluzole and edaravone are approved treatments; antisense oligonucleotide therapies targeting SOD1 and FUS are transforming outcomes for genetic subtypes.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Skeletal muscle atrophy and weakness resulting from loss of motor neuron innervation are shared hallmarks of amyotrophic lateral sclerosis (ALS) and age-associated sarcopenia. However, muscle wasting in ALS is rapid and severe, whereas sarcopenia progresses gradually over decades, peaking at an advanced age. The molecular mechanisms underlying muscle wasting in these conditions remain incompletely defined. Here, we used the SOD1G93A ALS mouse model and wild-type mice across the lifespan to generate an integrated single-nucleus transcriptomic atlas of skeletal muscle, mapping changes associated with ALS and aging. This atlas is complemented by structural and functional analyses. Our results identify transcriptionally distinct condition-specific myonuclear states, including disease-responsive programs within synaptic myonuclei at the neuromuscular junction, that are shared or distinct between the two conditions. Notably, at early stages, muscle from ALS mice exhibits molecular hallmarks of aged muscle at the myofiber level, indicating premature aging and reinforcing aging as a risk factor in ALS. At advanced disease stages and in old age, myonuclear subpopulations follow similar degenerative pathways in fast glycolytic fibers, consistent with their loss in both conditions. However, a distinct ALS-enriched myonuclei subpopulation displays uniquely regulated genes not observed in aged muscle, potentially underlying the more rapid and severe pathology observed in ALS. This atlas maps shared and divergent mechanisms of muscle degeneration in ALS and sarcopenia and provides a resource for identifying therapeutic targets tailored to each condition.
Common Questions
What is Motor Neuron Disease?
Motor neuron disease (MND), also known as ALS, is a progressive neurodegenerative condition that destroys the nerve cells controlling movement, leading to muscle weakness, paralysis, and eventually respiratory failure. Most cases are fatal within 2-5 years of diagnosis. Riluzole and edaravone are approved treatments; antisense oligonucleotide therapies targeting SOD1 and FUS are transforming outcomes for genetic subtypes.
How many clinical trials are available for Motor Neuron Disease?
RareWays currently indexes 706 clinical trials for Motor Neuron Disease, of which 109 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Motor Neuron Disease come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Motor Neuron Disease.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.